DESCRIPTION:

3rd Year Fellow talk covering updates in metastatic breast cancer

 

LEARNING OBJECTIVES

  • Describe the current FDA-approved indications for antibody-drug conjugates in metastatic breast cancer
  • Discuss current limitations in predicting antibody-drug conjugate response and selecting the optimal agent for each patient
  • Evaluate emerging strategies aimed at enhancing patient responses to antibody-drug conjugates, including biomarker-driven approaches and combination therapies
Session date: 
10/06/2025 - 12:00pm to 1:00pm CDT
Add to calendar: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Please login or create an account to proceed.
Speaker Name: 
Daniel Peiffer, MD, PhD